glp-1 and pancreas Biological Activities of GLP-1. The

Timing: Administer on the same day each week at any time

Both sites work well

Lancet Diabetes Endocrinol 6(4):275286 Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL et al (2023) The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

A key finding: at 24 weeks, participants had not yet reached a plateau, suggesting the weight loss curve with retatrutide may continue longer than with tirzepatide

Patients prioritizing long-term safety data benefit from tirzepatide more extensive clinical experience

BNF NICE